Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1 to 17 (canceled)

Claims 18 (new): A compound of Formula (I), or a salt, pro-drug, or solvate thereof:



(I)

wherein:

$\mathbf{R^1}$ is methyl;

$\mathbf{R^2}$ is selected from $-C(O)NR^4R^5$, $-SO_2NR^4R^5$ and $-S(O)_pR^4$;

HET-1 is a 5- or 6-membered, C-linked heteroaryl ring containing a nitrogen atom in the 2-position and optionally 1 or 2 further ring heteroatoms independently selected from O, N and S; which ring is optionally substituted on an available carbon atom, or on a ring nitrogen atom provided it is not thereby quaternised, with 1 or 2 substituents independently selected from R^6;

$\mathbf{R^3}$ is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy and cyano;

$\mathbf{R^4}$ is selected from hydrogen and (1-4C)alkyl;

$\mathbf{R^5}$ is hydrogen or (1-4C)alkyl;

$\mathbf{R^6}$ is independently selected from (1-4C)alkyl, halo, hydroxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkyl$S(O)_p$(1-4C)alkyl, amino(1-4C)alkyl,

(1-4C)alkylamino(1-4C)alkyl, di(1-4C)alkylamino(1-4C)alkyl and HET-4;

HET-4 is a 5- or 6-membered, C- or N- linked unsubstituted heteroaryl ring containing 1, 2, or 3 ring heteroatoms independently selected from O, N, and S;

p is independently at each occurrence 0, 1, or 2;

m is 0 or 1;

n is 0, 1, or 2;

provided that when m is 0, then n is 1 or 2.

Claim 19 (new): A compound of Formula (I), as claimed in Claim 18, which is selected from:

3-{4-[(dimethylamino)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-{4-[(methylamino)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

3-chloro-4-{3-(1-methylethyl)oxy-5-[(1,3-thiazol-2-ylamino)carbonyl]phenoxy}-N,N-dimethylbenzamide;

3-[4-(aminosulfonyl)-2-fluorophenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{2-chloro-4-[(dimethylamino)sulfonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-[4-(aminosulfonyl)-5-chloro-2-fluorophenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{2-chloro-4-[((1-methylethyl)amino)sulfonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfinyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-[4-(ethylthio)phenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-N-(1-methyl-1H-pyrazol-3-yl)-5-[4-(methylsulfonyl)phenoxy]benzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-1,3,4-thiadiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-pyridin-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-pyrazin-2-ylbenzamide;

3-(1-methylethyl)oxy-N-(5-methylisoxazol-3-yl)-5-[4-(methylsulfonyl)phenoxy]benzamide;

3-(1-methylethyl)oxy-N-isoxazol-3-yl-5-[4-(methylsulfonyl)phenoxy]benzamide;

N-[5-(2-furyl)-1,3,4-thiadiazol-2-yl]-3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]benzamide; and

N-{4-[(dimethylamino)methyl]-1,3-thiazol-2-yl}-3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]benzamide;

or a salt, pro-drug, or solvate thereof.

Claim 20 (new): A compound of Formula (I), as claimed in Claim 19, which is selected from:

3-chloro-4-{3-(1-methylethyl)oxy-5-[(1,3-thiazol-2-ylamino)carbonyl]phenoxy}-N,N-dimethylbenzamide;

3-[4-(aminosulfonyl)-2-fluorophenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{2-chloro-4-[(dimethylamino)sulfonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-[4-(aminosulfonyl)-5-chloro-2-fluorophenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{2-chloro-4-[((1-methylethyl)amino)sulfonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfinyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-[4-(ethylthio)phenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-N-(1-methyl-1H-pyrazol-3-yl)-5-[4-(methylsulfonyl)phenoxy]benzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-1,3,4-thiadiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]-N-pyridin-2-ylbenzamide;

3-(1-methylethyl)oxy-N-(5-methylisoxazol-3-yl)-5-[4-(methylsulfonyl)phenoxy]benzamide;

3-(1-methylethyl)oxy-N-isoxazol-3-yl-5-[4-(methylsulfonyl)phenoxy]benzamide;

N-[5-(2-furyl)-1,3,4-thiadiazol-2-yl]-3-(1-methylethyl)oxy-5-[4-(methylsulfonyl)phenoxy]benzamide; and

N-{4-[(dimethylamino)methyl]-1,3-thiazol-2-yl}-3-(1-methylethyl)oxy-5-[4-

(methylsulfonyl)phenoxy]benzamide;

or a salt, pro-drug, or solvate thereof.

Claim 21 (new): A compound of Formula (I) or a salt, pro-drug or solvate thereof:



(I)

wherein:

R^1 is methyl;

R^2 is selected from -C(O)-HET-3 and -SO_2-HET-3;

HET-1 is a 5- or 6-membered, C-linked heteroaryl ring containing a nitrogen atom in the 2-position and optionally 1 or 2 further ring heteroatoms independently selected from O, N and S; which ring is optionally substituted on an available carbon atom, or on a ring nitrogen atom provided it is not thereby quaternised, with 1 or 2 substituents independently selected from R^6;

HET-2 is a 4-, 5-, or 6-membered, C- or N-linked heterocyclyl ring containing 1, 2, 3, or 4 heteroatoms independently selected from O, N, and S, wherein a -CH_2- group can optionally be replaced by a -C(O)- , and wherein a sulphur atom in the heterocyclic ring may optionally be oxidised to a S(O) or $S(O)_2$ group, which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^7;

R^3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy, and cyano;

R^4 is selected from hydrogen; (1-4C)alkyl optionally substituted with 1 or 2 substituents independently selected from HET-2, -OR^5, -SO_2R^5, (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7), and -C(O)NR^5R^5; (3-6C)cycloalkyl (optionally substituted

with 1 group selected from R^7); and HET-2;

$\mathbf{R^5}$ is hydrogen or (1-4C)alkyl;

or $\mathbf{R^4}$ and $\mathbf{R^5}$ together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3;

$\mathbf{R^6}$ is independently selected from (1-4C)alkyl, halo, hydroxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkyl$S(O)_p$(1-4C)alkyl, amino(1-4C)alkyl, (1-4C)alkylamino(1-4C)alkyl, di(1-4C)alkylamino(1-4C)alkyl, and HET-4;

$\mathbf{R^7}$ is selected from $-OR^5$, (1-4C)alkyl, $-C(O)$(1-4C)alkyl, $-C(O)NR^4R^5$, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkyl, and $-S(O)_pR^5$;

HET-3 is an N-linked, 4-, 5-, or 6-membered, saturated or partially unsaturated heterocyclyl ring, optionally containing 1 or 2 further heteroatoms independently selected from O, N, and S, wherein a $-CH_2-$ group can optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^8; or

HET-3 is an N-linked, 7-membered, saturated or partially unsaturated heterocyclyl ring, optionally containing 1 further heteroatom independently selected from O, S, and N, wherein a $-CH_2-$ group can optionally be replaced by a -C(O)- group and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^8; or

HET-3 is an N-linked, 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclyl ring, optionally containing 1 further nitrogen atom wherein a $-CH_2-$ group can optionally be replaced by a -C(O)-; which ring is optionally substituted on an available carbon or nitrogen atom by 1 substituent selected from hydroxy and R^3;

$\mathbf{R^8}$ is selected from $-OR^5$, (1-4C)alkyl, $-C(O)$(1-4C)alkyl, $-C(O)NR^4R^5$, (1-4C)alkylamino, di(1-4C)alkylamino, HET-3 wherein said ring is unsubstituted, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkyl, and $-S(O)_pR^5$;

HET-4 is a 5- or 6-membered, C- or N- linked unsubstituted heteroaryl ring containing 1, 2, or 3

ring heteroatoms independently selected from O, N, and S;

p is independently at each occurrence 0, 1, or 2;

m is 1 and R^2 is in the para position relative to the ether linkage;

n is 0, 1, or 2.

Claim 22 (new): A compound of Formula (I) as claimed in Claim 21, or a salt, pro-drug, or solvate thereof, wherein HET-3 is a four to six membered ring.

Claim 23 (new): A compound of Formula (I) as claimed in Claim 21, which is selected from:

3-(1-methylethyl)oxy-5-{4-[(4-methylpiperazin-1-yl)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

1-(4-{3-(1-methylethyl)oxy-5-[(1,3-thiazol-2-ylamino)carbonyl]phenoxy}benzoyl)prolinamide;

3-(1-methylethyl)oxy-5-{4-[(3-oxopiperazin-1-yl)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

3-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-{4-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

3-{4-[(3-hydroxyazetidin-1-yl)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(morpholin-4-ylcarbonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-{4-[(4-acetylpiperazin-1-yl)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{[4-(azetidin-1-ylcarbonyl)phenyl]oxy}-5-[(1-methylethyl)oxy]-N-1,3-thiazol-2-ylbenzamide;

3-({4-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}oxy)-5-[(1-methylethyl)oxy]-N-1,3-thiazol-2-ylbenzamide;

3-{2-chloro-4-[(4-methylpiperazin-1-yl)sulfonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{[4-(azetidin-1-ylcarbonyl)-2-chlorophenyl]oxy}-5-[(1-methylethyl)oxy]-N-(1-methyl-1H-pyrazol-3-yl)benzamide;

3-{[4-(azetidin-1-ylcarbonyl)-2-fluorophenyl]oxy}-5-[(1-methylethyl)oxy]-N-(1-methyl-1H-pyrazol-3-yl)benzamide; and

3-{[4-(azetidin-1-ylcarbonyl)phenyl]oxy}-5-[(1-methylethyl)oxy]-N-(1-methyl-1H-pyrazol-3-yl)benzamide;

or a salt, pro-drug,or solvate thereof.

Claim 24 (new): A compound of Formula (I) as claimed in Claim 21, which is selected from:

3-(1-methylethyl)oxy-5-{4-[(4-methylpiperazin-1-yl)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

1-(4-{3-(1-methylethyl)oxy-5-[(1,3-thiazol-2-ylamino)carbonyl]phenoxy}benzoyl)prolinamide;

3-(1-methylethyl)oxy-5-{4-[(3-oxopiperazin-1-yl)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

3-{4-[(4-hydroxypiperidin-1-yl)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(4-{[4-(2-hydroxyethyl)piperazin-1-yl]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-{4-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]phenoxy}-N-1,3-thiazol-2-ylbenzamide;

3-{4-[(3-hydroxyazetidin-1-yl)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-(morpholin-4-ylcarbonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-{4-[(4-acetylpiperazin-1-yl)carbonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-{[4-(azetidin-1-ylcarbonyl)phenyl]oxy}-5-[(1-methylethyl)oxy]-N-1,3-thiazol-2-ylbenzamide;

3-({4-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}oxy)-5-[(1-methylethyl)oxy]-N-1,3-thiazol-2-ylbenzamide; and

3-{2-chloro-4-[(4-methylpiperazin-1-yl)sulfonyl]phenoxy}-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

or a salt, pro-drug, or solvate thereof.

Claim 25 (new): A compound of Formula (I), or a salt, pro-drug, or solvate thereof:



(I)

wherein:

$\mathbf{R^1}$ is methyl;

$\mathbf{R^2}$ is selected from $-C(O)NR^{41}R^{51}$, $-SO_2NR^{41}R^{51}$, and $-S(O)_pR^{41}$;

HET-1 is a 5- or 6-membered, C-linked heteroaryl ring containing a nitrogen atom in the 2-position and optionally 1 or 2 further ring heteroatoms independently selected from O, N, and S; which ring is optionally substituted on an available carbon atom, or on a ring nitrogen atom provided it is not thereby quaternised, with 1 or 2 substituents independently selected from R^6;

HET-2 is a 4-, 5-, or 6-membered, C- or N-linked heterocyclyl ring containing 1, 2, 3, or 4 heteroatoms independently selected from O, N, and S, wherein a $-CH_2-$ group can optionally be replaced by a -C(O)-, and wherein a sulphur atom in the heterocyclic ring may optionally be oxidised to a S(O) or $S(O)_2$ group, which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^7;

$\mathbf{R^3}$ is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy, and cyano;

$\mathbf{R^{41}}$ is selected from (1-4C)alkyl substituted with 1 or 2 substituents independently selected from HET-2, $-OR^5$, $-SO_2R^5$, (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7), and $-C(O)NR^5R^5$; (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7); and HET-2;

$\mathbf{R^{51}}$ is hydrogen or (1-4C)alkyl;

$\mathbf{R^4}$ is selected from (1-4C)alkyl optionally substituted with 1 or 2 substituents independently selected from HET-2, $-OR^5$, $-SO_2R^5$, (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7), and $-C(O)NR^5R^5$; (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7); and HET-2;

$\mathbf{R^5}$ is hydrogen or (1-4C)alkyl;

or $\mathbf{R^4}$ and $\mathbf{R^5}$ together with the nitrogen atom to which they are attached may form a heterocyclyl ring system as defined by HET-3;

$\mathbf{R^6}$ is independently selected from (1-4C)alkyl, halo, hydroxy(1-4C)alkyl, (1-4C)alkoxy(1-4C)alkyl, (1-4C)alkyl$S(O)_p$(1-4C)alkyl, amino(1-4C)alkyl, (1-4C)alkylamino(1-4C)alkyl, di(1-4C)alkylamino(1-4C)alkyl, and HET-4;

$\mathbf{R^7}$ is selected from $-OR^5$, (1-4C)alkyl, $-C(O)$(1-4C)alkyl, $-C(O)NR^4R^5$, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkyl, and $-S(O)_pR^5$;

HET-3 is an N-linked, 4-, 5-, or 6-membered, saturated or partially unsaturated heterocyclyl ring, optionally containing 1 or 2 further heteroatoms independently selected from O, N, and S, wherein a $-CH_2-$ group can optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^8; or

HET-3 is an N-linked, 7-membered, saturated or partially unsaturated heterocyclyl ring, optionally containing 1 further heteroatom independently selected from O, S, and N, wherein a $-CH_2-$ group can optionally be replaced by a -C(O)- group and wherein a sulphur atom in the ring may optionally be oxidised to a S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^8; or

HET-3 is an N-linked, 6- to 10-membered bicyclic saturated or partially unsaturated heterocyclyl ring, optionally containing 1 further nitrogen atom wherein a $-CH_2-$ group can optionally be replaced by a -C(O)-; which ring is optionally substituted on an available carbon or nitrogen atom by 1 substituent selected from hydroxy and R^3;

$\mathbf{R^8}$ is selected from $-OR^5$, (1-4C)alkyl, $-C(O)(1\text{-}4C)alkyl$, $-C(O)NR^4R^5$, (1-4C)alkylamino, di(1-4C)alkylamino, HET-3 wherein said ring is unsubstituted, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkyl, and $-S(O)_pR^5$;

HET-4 is a 5- or 6-membered, C- or N- linked unsubstituted heteroaryl ring containing 1, 2, or 3 ring heteroatoms independently selected from O, N, and S;

p is independently at each occurrence 0, 1, or 2;

m is 1 and R^2 is in the para position relative to the ether linkage;

n is 0, 1 or 2.

Claim 26 (new): A compound of Formula (I) as claimed in Claim 25, which is selected from:

3-(4-{[[2-(dimethylamino)-2-oxoethyl](methyl)amino]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(4-{[(2-hydroxyethyl)(methyl)amino]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(4-{[(2-hydroxyethyl)amino]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-({[2-(2-oxoimidazolidin-1-yl)ethyl]amino}carbonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-({[2-(methylamino)-2-oxoethyl]amino}carbonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-(4-{[(tetrahydro-2H-pyran-4-ylmethyl)amino]carbonyl}phenoxy)-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-(4-{[methyl(1-methylpiperidin-4-yl)amino]carbonyl}phenoxy)-N-1,3-thiazol-2-ylbenzamide;

3-[4-({[3-(1H-imidazol-1-yl)propyl]amino}carbonyl)phenoxy]-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-(4-{[(2-methoxyethyl)amino]carbonyl}phenoxy)-N-1,3-thiazol-2-ylbenzamide;

3-(4-{[(cyclopropylmethyl)amino]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-({[2-(methylsulfonyl)ethyl]amino}carbonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-[4-({[2-(2-oxopyrrolidin-1-yl)ethyl]amino}carbonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-(1-methylethyl)oxy-5-(4-{[(1-methylpiperidin-4-yl)amino]carbonyl}phenoxy)-N-1,3-thiazol-2-ylbenzamide;

3-(4-{[(1H-imidazol-2-ylmethyl)amino]carbonyl}phenoxy)-5-(1-methylethyl)oxy-N-1,3-thiazol-2-ylbenzamide;

3-chloro-4-{3-(1-methylethyl)oxy-5-[(1,3-thiazol-2-ylamino)carbonyl]phenoxy}-N-(2-methoxyethyl)benzamide; and

3-[(1-methylethyl)oxy]-5-[(4-{[methyl(1-methylpiperidin-4-yl)amino]carbonyl}phenyl)oxy]-N-(3-methyl-1,2,4-thiadiazol-5-yl)benzamide;

or a salt, pro-drug, or solvate thereof.

Claim 27 (new): A compound of Formula (I), or a salt, pro-drug, or solvate thereof:



(I)

wherein:

R^1 is methyl;

R^2 is HET-2;

HET-1 is a 5- or 6-membered, C-linked heteroaryl ring containing a nitrogen atom in the 2-position and optionally 1 or 2 further ring heteroatoms independently selected from O, N, and S; which ring is optionally substituted on an available carbon atom, or on a ring nitrogen atom provided it is not thereby quaternised, with 1 or 2 substituents independently selected from R^6;

HET-2 is a 4-, 5-, or 6-membered, C- or N-linked heterocyclyl ring containing 1, 2, 3, or 4 heteroatoms independently selected from O, N, and S, wherein a $-CH_2-$ group can optionally be replaced by a -C(O)-, and wherein a sulphur atom in the heterocyclic ring may optionally be oxidised to an S(O) or $S(O)_2$ group, which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^7;

R^3 is selected from halo, fluoromethyl, difluoromethyl, trifluoromethyl, methyl, methoxy, and cyano;

R^4 is selected from hydrogen; (1-4C)alkyl optionally substituted with 1 or 2 substituents independently selected from HET-2, $-OR^5$, $-SO_2R^5$, (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7), and $-C(O)NR^5R^5$; (3-6C)cycloalkyl (optionally substituted with 1 group selected from R^7); and HET-2;

R^5 is hydrogen or (1-4C)alkyl;

or **R^4** and **R^5** together with the nitrogen atom to which they are attached form a heterocyclyl ring system as defined by HET-3;

R^6 is independently selected from (1-4C)alkyl, halo, hydroxy(1-4C)alkyl, 1-4C)alkoxy(1-4C)alkyl, $(1\text{-}4C)alkylS(O)_p$(1-4C)alkyl, amino(1-4C)alkyl, (1-4C)alkylamino(1-4C)alkyl, di(1-4C)alkylamino(1-4C)alkyl, and HET-4;

R^7 is selected from $-OR^5$, (1-4C)alkyl, -C(O)(1-4C)alkyl, $-C(O)NR^4R^5$, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkyl, and $-S(O)_pR^5$;

HET-3 is an N-linked, 4-, 5-, or 6-membered, saturated or partially unsaturated heterocyclyl ring, optionally containing 1 or 2 further heteroatoms independently selected from O, N, and S,

wherein a -CH_2- group can optionally be replaced by a -C(O)- and wherein a sulphur atom in the ring may optionally be oxidised to an S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^8; or

HET-3 is an N-linked, 7-membered, saturated or partially unsaturated heterocyclyl ring, optionally containing 1 further heteroatom independently selected from O, S, and N, wherein a -CH_2- group can optionally be replaced by a -C(O)- group and wherein a sulphur atom in the ring may optionally be oxidised to an S(O) or $S(O)_2$ group; which ring is optionally substituted on an available carbon or nitrogen atom by 1 or 2 substituents independently selected from R^8; or

HET-3 is an N-linked, 6- to 7-membered bicyclic saturated or partially unsaturated heterocyclyl ring, optionally containing 1 further nitrogen atom, wherein a -CH_2- group can optionally be replaced by a -C(O)-; which ring is optionally substituted on an available carbon or nitrogen atom by 1 substituent selected from hydroxy and R^3;

$\mathbf{R^8}$ is selected from -OR^5, (1-4C)alkyl, -C(O)(1-4C)alkyl, -C(O)NR^4R^5, (1-4C)alkylamino, di(1-4C)alkylamino, HET-3 wherein said ring is unsubstituted, (1-4C)alkoxy(1-4C)alkyl, hydroxy(1-4C)alkyl, and -$S(O)_pR^5$;

HET-4 is a 5- or 6-membered, C- or N- linked unsubstituted heteroaryl ring containing 1, 2, or 3 ring heteroatoms independently selected from O, N, and S;

p is independently at each occurrence 0, 1, or 2;

m is 1 and R^2 is in the para position relative to the ether linkage;

n is 0, 1, or 2.

Claim 28 (new): A compound of Formula (I), as claimed in Claim 27, which is selected from:

3-(1-methylethyl)oxy-5-[4-(1,3,4-oxadiazol-2-yl)phenoxy]-N-1,3-thiazol-2-ylbenzamide;

3-[4-(3,5-dimethylisoxazol-4-yl)phenoxy]-5-(1-methylethyl)oxy-N-(1-methyl-1H-pyrazol-3-yl)benzamide; and

3-[(4-furan-3-ylphenyl)oxy]-5-[(1-methylethyl)oxy]-N-(1-methyl-1H-pyrazol-3-yl)benzamide;

or a salt, pro-drug, or solvate thereof.

Claim 29 (new): A compound of Formula (I) as claimed in Claim 18, Claim 21, Claim 25, or Claim 27 or a salt, pro-drug, or solvate thereof wherein R^1 has the (S) configuration.

Claim 30 (new): A compound of Formula (I) as claimed in Claim 18, Claim 21, Claim 25, or Claim 27 or a salt, pro-drug, or solvate thereof, wherein HET-1 is a 5-membered ring.

Claim 31 (new): A pharmaceutical composition comprising a compound as claimed in Claim 18, Claim 21, Claim 25, or Claim 27, or a salt, pro-drug, or solvate thereof, together with a pharmaceutically acceptable diluent or carrier.

Claim 32 (new): A method of treating GLK mediated diseases comprising administering an effective amount of a compound of Formula (I) as claimed in Claim 18, Claim 21, Claim 25, or Claim 27 or a salt, pro-drug, or solvate thereof, to a mammal in need of such treatment.

Claim 33 (new): The method of Claim 32 wherein the GLK mediated disease is type 2 diabetes.

Claim 34 (new): A process for the preparation of a compound of Formula (I) or a salt, pro-drug, or solvate thereof as claimed in Claim 18, Claim 21, Claim 25, or Claim 27, comprising:

(a) reacting an acid of Formula (III) or activated derivative thereof with a compound of Formula (IV),



(III)

(IV);

or

(b) reacting a compound of Formula (V) with a compound of Formula (VI),

(V)



(VI)

wherein X^1 is a leaving group and X^2 is a hydroxyl group; or X^1 is a hydroxyl group and X^2 is a leaving group;

or

reacting the compound of Formula (V) with the intermediate ester Formula (VII), wherein P^1 is a protecting group followed by ester hydrolysis and amide formation;

(V)



(VII)

or

(c) reacting a compound of Formula (VIII) with a compound of Formula (IX)



(VIII)



(IX)

wherein X^3 is a leaving group or an organometallic reagent and X^4 is a hydroxyl group; or X^3 is a hydroxyl group and X^4 is a leaving group or an organometallic reagent;

or

reacting a compound of Formula (VIII) with the intermediate ester of Formula (X), followed

by ester hydrolysis and amide formation;



(VIII) (X)

or

(d) reacting a compound of Formula (XI) with a compound of Formula (XII),



(XI) (XII);

wherein X^5 is a leaving group;

or

e) when R^2 is of the Formula $-C(O)NR^4R^5$, reacting a compound of the Formula:



with a compound of the Formula HNR^4R^5;

and thereafter, if necessary:

i) converting a compound of Formula (I) into another compound of Formula (I);

ii) removing any protecting groups; and/or

iii) forming a salt, pro-drug, or solvate.